Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Change in Cash (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Change in Cash for 9 consecutive years, with -$176.6 million as the latest value for Q4 2025.

  • Quarterly Change in Cash changed N/A to -$176.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$17.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$17.8 million for FY2025, 78.2% up from the prior year.
  • Change in Cash for Q4 2025 was -$176.6 million at Soleno Therapeutics, down from $170.2 million in the prior quarter.
  • The five-year high for Change in Cash was $170.2 million in Q3 2025, with the low at -$176.6 million in Q4 2025.